macs cell separation column ls miltenyi biotec (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
99
Structured Review
Miltenyi Biotec
macs cell separation column ls miltenyi biotec
Macs Cell Separation Column Ls Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 8894 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+separation+column/LS+Columns/pm42248140-238-219-224
Average 99 stars, based on 8894 article reviews
Macs Cell Separation Column Ls Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 8894 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+separation+column/LS+Columns/pm42248140-238-219-224
Average 99 stars, based on 8894 article reviews
macs cell separation column ls miltenyi biotec - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Magnetic Cell Separation:Article Title: Attenuation of HOIL-1L ligase activity promotes systemic autoimmune disorders by augmenting linear ubiquitin signaling Article Snippet: The attached cells were seeded in 6-well plates and stimulated with LPS ( Escherichia coli 055: B5; MilliporeSigma, 10 ng/mL) or R848 (catalog tlrl-r848-5; InvivoGen, 1 mg/mL) for the indicated times. .. Splenic B cells were positively selected using anti-CD19 MicroBeads (Miltenyi Biotec) and a Article Title: Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof Article Snippet: Briefly, first the PBMC was washed with PBS (Gibco, Catalog No: 14190-136), then the PBMC was resuspended at 107 cells per 40 μL of separation buffer (PBS containing 2 mM EDTA, 0.5% BSA, pH=7.2) (the following usage amounts are all based on 107 cells), and 10 μL of Pan T cell Biotin Antibody Cocktail was added and incubated at 4° C. for 5 minutes. .. Then 30 μL of separation buffer and 20 μL of Pan T cell MicroBead Cocktail were added, and incubated at 4° C. for 10 minutes, passed through the Article Title: Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion Article Snippet: .. We isolated hUCB CD34 + cells from 2 patients using the Miltenyi CD34 Microbead Kit and Article Title: Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion Article Snippet: .. We isolated hUCB CD34+ cells from 2 patients using the Miltenyi CD34 Microbead Kit and Article Title: Mutant KRAS Peptide Targeted CAR-T Cells Engineered for Cancer Therapy Article Snippet: .. On day 7 of expansion, edited TCR − CAR-T cell products were purified by negative selection with anti-biotin microbeads (Miltenyi Cat# 130-105-637) and biotin conjugated anti-CD3 (Biolegend, Cat# 317320) on a Article Title: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Article Snippet: Report Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy Graphical abstract Highlights • Engineered scFvs target mutant KRAS with high affinity and specificity in vitro • Oncogenic KRAS directed NeoCARs exhibit anti-tumor response in vitro and in vivo • NeoCARs armored with inducible IL-12 upregulate antigen availability and enhance killing • TCR knockout improves the safety of iIL-12 NeoCARs in vivo Authors Alexander Benton, Jiageng Liu, Mathilde A. Poussin, ..., Matthew D. Beasley, Ben R. Kiefel, Daniel J. Powell, Jr.. Correspondence poda@pennmedicine.upenn.edu In brief Benton et al. identify binders against common mutant KRAS neoantigens and create peptide-centric CAR-T cells (NeoCARs).. NeoCARs demonstrate a robust anti-tumor response against cancer cells expressing mutant KRAS peptides by MHC, both in vitro and in vivo. Article Title: Targeting CAFs-derived PCSK6 inhibits redistribution of PD-L1 and restores response of CD8 + T cells against colorectal cancer. Article Snippet: Isolation of PCSK6+CAFs by fluorescence activated cell sorting FSP+ cells were then positively selected using a relevant Multisort Microbeads (Miltenyi Biotec). .. After the removal of the FSP Multisort Microbeads using an enzyme (multisort release reagent), FSP+ cells were further stained with an FITC-conjugated mAb recognizing CXCR4 (Biotechne, USA) and CXCR4+ cells were obtained by positive selection using anti-FITC microbeads through a Incubation:Article Title: Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof Article Snippet: Briefly, first the PBMC was washed with PBS (Gibco, Catalog No: 14190-136), then the PBMC was resuspended at 107 cells per 40 μL of separation buffer (PBS containing 2 mM EDTA, 0.5% BSA, pH=7.2) (the following usage amounts are all based on 107 cells), and 10 μL of Pan T cell Biotin Antibody Cocktail was added and incubated at 4° C. for 5 minutes. .. Then 30 μL of separation buffer and 20 μL of Pan T cell MicroBead Cocktail were added, and incubated at 4° C. for 10 minutes, passed through the Isolation:Article Title: Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion Article Snippet: .. We isolated hUCB CD34 + cells from 2 patients using the Miltenyi CD34 Microbead Kit and Article Title: Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion Article Snippet: .. We isolated hUCB CD34+ cells from 2 patients using the Miltenyi CD34 Microbead Kit and Purification:Article Title: Mutant KRAS Peptide Targeted CAR-T Cells Engineered for Cancer Therapy Article Snippet: .. On day 7 of expansion, edited TCR − CAR-T cell products were purified by negative selection with anti-biotin microbeads (Miltenyi Cat# 130-105-637) and biotin conjugated anti-CD3 (Biolegend, Cat# 317320) on a Article Title: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Article Snippet: Report Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy Graphical abstract Highlights • Engineered scFvs target mutant KRAS with high affinity and specificity in vitro • Oncogenic KRAS directed NeoCARs exhibit anti-tumor response in vitro and in vivo • NeoCARs armored with inducible IL-12 upregulate antigen availability and enhance killing • TCR knockout improves the safety of iIL-12 NeoCARs in vivo Authors Alexander Benton, Jiageng Liu, Mathilde A. Poussin, ..., Matthew D. Beasley, Ben R. Kiefel, Daniel J. Powell, Jr.. Correspondence poda@pennmedicine.upenn.edu In brief Benton et al. identify binders against common mutant KRAS neoantigens and create peptide-centric CAR-T cells (NeoCARs).. NeoCARs demonstrate a robust anti-tumor response against cancer cells expressing mutant KRAS peptides by MHC, both in vitro and in vivo. Selection:Article Title: Mutant KRAS Peptide Targeted CAR-T Cells Engineered for Cancer Therapy Article Snippet: .. On day 7 of expansion, edited TCR − CAR-T cell products were purified by negative selection with anti-biotin microbeads (Miltenyi Cat# 130-105-637) and biotin conjugated anti-CD3 (Biolegend, Cat# 317320) on a Article Title: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Article Snippet: Report Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy Graphical abstract Highlights • Engineered scFvs target mutant KRAS with high affinity and specificity in vitro • Oncogenic KRAS directed NeoCARs exhibit anti-tumor response in vitro and in vivo • NeoCARs armored with inducible IL-12 upregulate antigen availability and enhance killing • TCR knockout improves the safety of iIL-12 NeoCARs in vivo Authors Alexander Benton, Jiageng Liu, Mathilde A. Poussin, ..., Matthew D. Beasley, Ben R. Kiefel, Daniel J. Powell, Jr.. Correspondence poda@pennmedicine.upenn.edu In brief Benton et al. identify binders against common mutant KRAS neoantigens and create peptide-centric CAR-T cells (NeoCARs).. NeoCARs demonstrate a robust anti-tumor response against cancer cells expressing mutant KRAS peptides by MHC, both in vitro and in vivo. Article Title: Targeting CAFs-derived PCSK6 inhibits redistribution of PD-L1 and restores response of CD8 + T cells against colorectal cancer. Article Snippet: Isolation of PCSK6+CAFs by fluorescence activated cell sorting FSP+ cells were then positively selected using a relevant Multisort Microbeads (Miltenyi Biotec). .. After the removal of the FSP Multisort Microbeads using an enzyme (multisort release reagent), FSP+ cells were further stained with an FITC-conjugated mAb recognizing CXCR4 (Biotechne, USA) and CXCR4+ cells were obtained by positive selection using anti-FITC microbeads through a Staining:Article Title: Targeting CAFs-derived PCSK6 inhibits redistribution of PD-L1 and restores response of CD8 + T cells against colorectal cancer. Article Snippet: Isolation of PCSK6+CAFs by fluorescence activated cell sorting FSP+ cells were then positively selected using a relevant Multisort Microbeads (Miltenyi Biotec). .. After the removal of the FSP Multisort Microbeads using an enzyme (multisort release reagent), FSP+ cells were further stained with an FITC-conjugated mAb recognizing CXCR4 (Biotechne, USA) and CXCR4+ cells were obtained by positive selection using anti-FITC microbeads through a Single Cell:Article Title: Targeting CAFs-derived PCSK6 inhibits redistribution of PD-L1 and restores response of CD8 + T cells against colorectal cancer. Article Snippet: Isolation of PCSK6+CAFs by fluorescence activated cell sorting FSP+ cells were then positively selected using a relevant Multisort Microbeads (Miltenyi Biotec). .. After the removal of the FSP Multisort Microbeads using an enzyme (multisort release reagent), FSP+ cells were further stained with an FITC-conjugated mAb recognizing CXCR4 (Biotechne, USA) and CXCR4+ cells were obtained by positive selection using anti-FITC microbeads through a |